



DT02 Rec'd PCT

11 JAN 2005

PCT #3

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)	Romero, et al.	Examiner:	Unassigned
Serial No.:	10/511,384	Group Art Unit:	Unassigned
Confirmation No:	Unassigned	Docket:	976-19 PCT/US
Filed:	October 15, 2004	Dated:	January 7, 2005
For:	ACTIVE ANTIANGIOGENIC THERAPY		

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

*I hereby certify this correspondence is being deposited
with the United States Postal Service as first class mail,
postpaid in an envelope, addressed to:
Commissioner for Patents, P.O. Box 1450,
Alexandria, Virginia 22313-1450
on January 7, 2005*

Signed: _____

INFORMATION DISCLOSURE STATEMENT

Sir:

In order to fulfill the requirements of candor and good faith set forth in 37 C.F.R.
§1.56, Applicants submit herewith the following Information Disclosure Statement in
accordance with the provisions of 37 C.F.R. §1.97 and §1.98.

FOREIGN PATENT DOCUMENTS

<u>COUNTRY</u>	<u>PUBLICATION NO.</u>	<u>PUBLICATION DATE</u>
PCT	WO 00/53219	September 14, 2000

1


NON-PATENT PUBLICATIONS

1. Davidoff, Andrew M., et al., "Bone Marrow-derived Cells Contribute to Tumor Neovasculation and, When Modified to Express an Angiogenesis Inhibitor, Can Restrict Tumor Growth in Mice", *Clinical Cancer Research* 2001, 7:2870-2879.
2. Prewett, Marie, et al., "Antivascular Endothelial Growth Factor Receptor (Fetal Liver Kinase 1) Monoclonal Antibody Inhibits Tumor Angiogenesis and Growth of Several Mouse and Human Tumors", *Cancer Research* 1999, 59:5209-5218.
3. Wei, Yu-quan, et al., "Immunogene therapy of tumors with vaccine based on *Xenopus* homologous vascular endothelial growth factor as a model antigen", *PNAS* 2001, 98(20):11545-11550.

The above-referenced documents are listed on PTO Form 1449. We have enclosed the cited documents to facilitate reference to them.


Applicants are not aware of any other references to be identified at this time. If the Examiner has any questions or comments relating to the present application, he or she is respectfully invited to contact Applicants' agent at the telephone number set forth below.

Respectfully submitted,



Edna I. Gergel, Ph.D.
Registration No.: 50,819
Agent for Applicant(s)

HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, New York 11791
(516) 822-3550
EIG:jlw
199159_1

FORM 1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-32) PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.
976-19 PCT/USSERIAL NO.
10/511,384APPLICANT
Romero, et al.CONFIRMATION NO.
UnassignedFILING DATE
October 15, 2004GROUP
Unassigned

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
		WO 00/53219	9/14/00	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		1.	Davidoff, Andrew M., et al., "Bone Marrow-derived Cells Contribute to Tumor Neovasculature and, When Modified to Express an Angiogenesis Inhibitor, Can Restrict Tumor Growth in Mice", <i>Clinical Cancer Research</i> 2001, 7:2870-2879.
		2.	Prewett, Marie, et al., "Antivascular Endothelial Growth Factor Receptor (Fetal Liver Kinase 1) Monoclonal Antibody Inhibits Tumor Angiogenesis and Growth of Several Mouse and Human Tumors", <i>Cancer Research</i> 1999, 59:5209-5218.
		3.	Wei, Yu-quan, et al., "Immunogene therapy of tumors with vaccine based on <i>Xenopus</i> homologous vascular endothelial growth factor as a model antigen", <i>PNAS</i> 2001, 98(20):11545-11550.

199164_1

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.